COVID-19 adenoviral but not mRNA vaccines are associated with adverse cardiovascular events
1. The first dose of adenoviral-based Oxford-AstraZeneca and Janssen vaccines was associated with acute myocardial infarction and pulmonary embolism. 2. ...
Tag: COVID-19 Vaccine
Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection
1. Following a SARS-CoV-2 (COVID-19) infection, patients who received the Moderna mRNA-1273 vaccine were less likely to develop anti-nucleocapsid antibodies ...
![ABCD2 Score: Predicting Early Stroke Risk After Transient Ischemic Attack (TIA) [Classics Series]](https://www.2minutemedicine.com/wp-content/uploads/2013/05/web-cover-classics-with-logo-medicine-BW-small-jpg-350x250.jpg){kind=logo}
Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]
This study summary is an excerpt from the book 2 Minute Medicine's The Classics in Medicine: Summaries of the Landmark ...
AZD7442 monoclonal antibodies are efficacious in the prevention of COVID-19
1. Compared to placebo, intramuscular AZD7442 had a relative risk reduction of 76.7% for symptomatic incident coronavirus disease 2019 (COVID-19). ...
The Moderna mRNA vaccine prevents COVID-19 infection in adolescents
1. The Moderna mRNA vaccine significantly decreased the risk of contracting coronavirus disease 2019 (COVID-19) in adolescents. 2. For adolescents ...
Small-magnitude differences in risk of adverse events identified between the BNT162b2 and mRNA-1273 across 38 weeks follow-up
1. Among a large cohort of US veterans, the 38-week risks of adverse events were low in both vaccine groups, ...
The ZF2001 vaccine is safe and effective at preventing COVID-19 in adults
1. The ZF2001 vaccine significantly reduces the risk of contracting symptomatic coronavirus disease 2019 (COVID-19) as compared to a placebo ...
Single-dose Ad26.COV2.S vaccine provides moderate protection against Covid-19 related outcomes
1. One dose of Ad26.COV2.S (Johnson & Johnson) provided some protection against moderate to severe Covid-19-related infection and medical intervention. ...
BNT162b2 safe and efficacious in children 5 to 11 years of age
1. A two-dose regimen of BNT162b2 at 10μg elicits a sufficient immune response in children 5 – 11 years of ...
Covid-19 vaccines and boosters are transiently effective against the Omicron
1. Two doses of BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccine provided good protection against the Omicron (B.1.1.529) variant but rapidly ...
